Literature DB >> 25427340

Botulinum toxin injection into the lacrimal gland for treatment of proximal nasolacrimal duct obstructions in children.

H Sprague Eustis, Allison Babiuch.   

Abstract

The authors retrospectively evaluated the use of botulinum toxin injections to treat epiphora in children secondary to proximal obstruction of the nasolacrimal drainage system. Three patients (ages 8, 9, and 16 years) received botulinum toxin injections in the palpebral portion of the lacrimal gland. Two patients experienced symptomatic relief immediately following botulinum toxin injection. Both required subsequent injections, with an average symptomatic relief lasting 7 months. The only noted side effect was papillary conjunctivitis in one patient that resolved without treatment. The third patient was lost to follow-up. Although conjunctival dacryocystorhinostomy with Jones tube is the surgical procedure of choice for treating proximal lacrimal system obstruction, complication rates in children are high. Botulinum toxin injections provide a safe and effective alternative. Copyright 2014, SLACK Incorporated.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25427340     DOI: 10.3928/01913913-20141120-02

Source DB:  PubMed          Journal:  J Pediatr Ophthalmol Strabismus        ISSN: 0191-3913            Impact factor:   1.402


  3 in total

1.  Repeated injections of botulinum toxin-A for epiphora in lacrimal drainage disorders: qualitative and quantitative assessment.

Authors:  Chanjoo Ahn; Sunah Kang; Ho-Seok Sa
Journal:  Eye (Lond)       Date:  2019-02-14       Impact factor: 3.775

Review 2.  Lacrimal gland botulinum toxin injection for epiphora management.

Authors:  Johnathan Jeffers; Katherine Lucarelli; Sruti Akella; Pete Setabutr; Ted H Wojno; Vinay Aakalu
Journal:  Orbit       Date:  2021-08-15

Review 3.  A Review of Periocular Botulinum Neurotoxin on the Tear Film Homeostasis and the Ocular Surface Change.

Authors:  Ren-Wen Ho; Po-Chiung Fang; Cheng-Hsien Chang; Yu-Peng Liu; Ming-Tse Kuo
Journal:  Toxins (Basel)       Date:  2019-01-24       Impact factor: 4.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.